Table 2.
Adverse events with capecitabine adjuvant chemotherapy
| Adverse events | Control group (n = 59) | PBPM group (n = 110) | p-value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy regimens | All (%) | Grade 0 | Grade 1 | Grade 2 | Grade 3 | All (%) | Grade 0 | Grade 1 | Grade 2 | Grade 3 | |
| Hand-foot syndrome | 59 (100) | 25 | 31 | 3 | 0 | 110 (100) | 66 | 39 | 5 | 0 | 0.0382 |
| XELOX | 34 (57.6) | 16 | 17 | 1 | 0 | 55 (50.0) | 33 | 20 | 2 | 0 | 0.2720 |
| XELOX + Bevacizumab | 16 (27.1) | 6 | 9 | 1 | 0 | 30 (27.3) | 18 | 12 | 0 | 0 | 0.1162 |
| Capecitabine | 9 (15.3) | 3 | 5 | 1 | 0 | 24 (21.8) | 14 | 7 | 3 | 0 | 0.3135 |
| XELIRI + Bevacizumab | – | – | – | – | – | 1 (0.9) | 1 | 0 | 0 | 0 | – |
| Constipation | 42 (71.2) | 36 | 5 | 1 | 0 | 44 (40.0) | 43 | 1 | 0 | 0 | 0.0430 |
| Diarrhea | 44 (74.6) | 43 | 1 | 0 | 0 | 51 (46.4) | 45 | 6 | 0 | 0 | 0.3227 |
| Nausea/vomiting | 44 (74.6) | 44 | 0 | 0 | 0 | 60 (54.5) | 52 | 7 | 0 | 1 | 0.0124 |
| Stomatitis | 41 (69.5) | 41 | 0 | 0 | 0 | 40 (36.4) | 37 | 2 | 1 | 0 | 0.0782 |
| Loss of appetite | 43 (72.9) | 42 | 1 | 0 | 0 | 66 (60.0) | 52 | 10 | 4 | 0 | 0.0015 |
| Fatigue | 41 (69.5) | 34 | 7 | 0 | 0 | 52 (47.3) | 38 | 13 | 1 | 0 | 0.0010 |
| Rash | 36 (61.0) | 36 | 0 | 0 | 0 | 37 (33.6) | 37 | 0 | 0 | 0 | NA |
| Fever | 37 (62.7) | 37 | 0 | 0 | 0 | 38 (34.5) | 37 | 1 | 0 | 0 | 0.3370 |
| Watering eyes | 36 (61.0) | 36 | 0 | 0 | 0 | 32 (29.1) | 27 | 5 | 0 | 0 | 0.0150 |
| Hypertension | 57 (96.6) | 57 | 0 | 0 | 0 | 110 (100) | 109 | 1 | 0 | 0 | 0.4794 |
| Peripheral neuropathy | 57 (96.6) | 49 | 7 | 1 | 0 | 47 (42.7) | 2 | 39 | 5 | 1 | 1.0040 |
Abbreviation: XELOX, capecitabine plus oxaliplatin: XELIRI, capecitabine plus irinotecan: NA, not applicable